News
ADAG
2.625
-5.58%
-0.155
Weekly Report: what happened at ADAG last week (0928-1002)?
Weekly Report · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Adagene (ADAG) and Inventiva (IVA)
TipRanks · 09/29 10:50
Weekly Report: what happened at ADAG last week (0921-0925)?
Weekly Report · 09/28 10:05
Adagene Announces Finance Executive Resignation Effective September 30, 2026
TipRanks · 09/25 21:01
Adagene Gains NMPA Clearance On Phase 1 For ADG138 In Solid Tumors, Set To Begin In Q4 '26
NASDAQ · 09/22 20:21
Adagene Wins NMPA IND Clearance for Novel HER2xCD3 T-Cell Engager ADG138
TipRanks · 09/22 12:27
Adagene announces China’s NMPA approved IND for ADG138
TipRanks · 09/22 12:05
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology
Benzinga · 09/22 12:01
Weekly Report: what happened at ADAG last week (0914-0918)?
Weekly Report · 09/21 10:05
Adagene CEO Makes Bold Insider Move With Fresh Stock Purchase
TipRanks · 09/18 02:05
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Adagene (ADAG) and Medtronic (MDT)
TipRanks · 09/14 10:31
Weekly Report: what happened at ADAG last week (0907-0911)?
Weekly Report · 09/14 10:10
Analysts’ Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)
TipRanks · 09/11 11:40
Adagene’s Platform Partnerships and Muzastotug Catalysts Support Buy Rating, Price Target Unchanged at $8
TipRanks · 09/10 15:05
Adagene Deepens Third Arc Bio Partnership as First SAFEbody-Based CD3 Lead Selected
TipRanks · 09/10 12:28
Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene
Benzinga · 09/10 12:07
Adagene Price Target Announced at $9.00/Share by Chardan Capital
Dow Jones · 09/10 11:57
Adagene Initiated at Buy by Chardan Capital
Dow Jones · 09/10 11:57
Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Benzinga · 09/10 11:47
Adagene initiated with a Buy at Chardan
TipRanks · 09/10 10:35
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.